ARQT - Arcutis Biotherapeutics, Inc.

QQQ $ 475.24 $ 1.81 (0.38 %)

DIA $ 414.72 $ 2.09 (0.51 %)

SPY $ 561.69 $ 1.42 (0.25 %)

TLT $ 100.54 $ 0.06 (0.06 %)

GLD $ 238.52 $ 0.93 (0.39 %)

Previous Close

$ 10.52

Open

$ 10.51

Bid

$ 10.63 x 100

Ask

$ 10.64 x 300

Day's Range

$ 10.36 - $ 10.68

52 Week Range

$ 1.76 - $ 13.17

Volume

1,486,058

Average Volume

Market Cap

1.23B

Beta (5Y Monthly)

$ 0.47

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-14-2024	06-30-2024	10-Q
2	05-14-2024	03-31-2024	10-Q
3	02-27-2024	12-31-2023	10-K
4	11-03-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-04-2022	06-30-2022	10-Q
10	05-05-2022	03-31-2022	10-Q
11	02-22-2022	12-31-2021	10-K
12	11-04-2021	09-30-2021	10-Q
13	08-05-2021	06-30-2021	10-Q
14	05-06-2021	03-31-2021	10-Q
15	02-16-2021	12-31-2020	10-K
16	11-05-2020	09-30-2020	10-Q
17	08-11-2020	06-30-2020	10-Q
18	05-12-2020	03-31-2020	10-Q
19	03-19-2020	12-31-2019	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Arcutis Biotherapeutics Completes Enrollme...
09/05/2024 12:06:46

Assessing Arcutis Biotherapeutics: Insight...
08/28/2024 13:00:26

Jefferies Initiates Coverage On Arcutis Bi...
08/28/2024 12:19:44

Jefferies analyst Kambiz Yazdi initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy rating and announces P...

Arcutis Biotherapeutics Announces Long-Ter...
08/28/2024 12:07:39

cava-group-posts-strong-q2-results-joins-bilibili-workday-and-other-big-stocks-moving-higher-on-friday

CAVA Group Posts Strong Q2 Results, Joins ...
08/23/2024 14:22:49

titan-machinery-reports-weak-preliminary-results-joins-precigen-gogoro-and-other-big-stocks-moving-lower-in-thursday-pre-market-session

Titan Machinery Reports Weak Preliminary R...
08/15/2024 12:11:53

Needham Reiterates Buy on Arcutis Biothera...
08/15/2024 10:34:31

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.

Arcutis Biotherapeutics Q2 2024 GAAP EPS $...
08/14/2024 20:01:32

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate ...

Peeling Back The Layers: Exploring Arcutis...
07/30/2024 16:00:49

Needham Reiterates Buy on Arcutis Biothera...
07/30/2024 10:24:06

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.

Arcutis Launches ZORYVE Cream for Atopic D...
07/29/2024 11:32:19

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inn...

Arcutis Submits Supplemental NDA For ZORYV...
07/23/2024 12:17:08

Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp O...

Arcutis To Host ZORYVE Cream 0.15% FDA App...
07/22/2024 12:06:50

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...

fda-approves-expanded-use-of-arcutis-biotherapeutics-eczema-drug-for-patients-as-young-as-6-years

FDA Approves Expanded Use Of Arcutis Bioth...
07/10/2024 15:23:23

FDA approved Arcutis Biotherapeutics' sNDA for Zoryve cream 0.15% for mild to moderate atopic dermatitis in patients aged s...

Arcutis Biotherapeutics Stock: A Deep Dive...
07/10/2024 12:00:16

Needham Reiterates Buy on Arcutis Biothera...
07/10/2024 10:26:05

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $18 price target.

Trading Halt: Halt status updated at 5:15:...
07/09/2024 21:15:04

Arcutis Biotherapeutics Says FDA Approved ...
07/09/2024 20:55:25

ZORYVE is a once-daily, steroid-free cream that provides rapid disease clearance and significant reduction in itch and has been...

Trading Halt: Halted at 4:25:38 p.m. ET - ...
07/09/2024 20:25:42

Arcutis Provides Update On sNDA for Roflum...
07/09/2024 12:33:20

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful inno...